PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Thirty-three patients with advanced breast cancer were treated with PALA at a schedule of 1500 mg/m2/day for 5 days every 3 weeks. Time to progression varied from 4-305 days from the start of therapy (median, 49 days) with 3 partial responses (9%) for 231, 180, and 64 days, respectively. Toxicity was considerable, with severe skin and mucosal toxicity occurring in 48% and 39% of cases, respectively. Hematologic toxicity was usually mild. We conclude PALA has limited activity in advanced breast cancer, but may be of advantage in combination chemotherapy because of the relative bone marrow-sparing properties.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001224:Aspartic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009092:Mucous Membrane / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D010746:Phosphonoacetic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D012867:Skin / Q000187:drug effects; D014481:United States
D000970:Antineoplastic Agents; D009943:Organophosphorus Compounds; D001224:Aspartic Acid; C013195:sparfosic acid; D010746:Phosphonoacetic Acid